- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.04. | Greenwich LifeSciences verschiebt Vorlage des Jahresberichts | 1 | Investing.com Deutsch | ||
| 30.04. | Greenwich LifeSciences delays annual report filing | 1 | Investing.com | ||
| GREENWICH LIFESCIENCES Aktie jetzt für 0€ handeln | |||||
| 30.04. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update Regarding Form 10-K Filing | 2 | GlobeNewswire (USA) | ||
| 23.04. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026 | 2 | GlobeNewswire (USA) | ||
| 22.04. | Greenwich LifeSciences receives Nasdaq notice regarding late Form 10-K filing | 1 | Seeking Alpha | ||
| 22.04. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing | 640 | GlobeNewswire (Europe) | STAFFORD, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial... ► Artikel lesen | |
| 20.04. | Greenwich LifeSciences: Aktie steigt nach positiven Studiendaten zu Brustkrebsimpfstoff | 1 | Investing.com Deutsch | ||
| 20.04. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026 | 1 | GlobeNewswire (USA) | ||
| 14.04. | Greenwich LifeSciences reports Q1 cash balance of $10.5 million | 1 | Investing.com | ||
| 14.04. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Financing Strategy | 279 | GlobeNewswire (Europe) | STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial... ► Artikel lesen | |
| 07.04. | Greenwich LifeSciences files patent claims for breast cancer therapy | 1 | Investing.com | ||
| 07.04. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential | 256 | GlobeNewswire (Europe) | STAFFORD, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial... ► Artikel lesen | |
| 31.03. | Greenwich LifeSciences, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 19.03. | Greenwich LifeSciences: Phase-III-Studie wird auf City of Hope-Standorte ausgeweitet | 3 | Investing.com Deutsch | ||
| 19.03. | Greenwich LifeSciences expands Phase III trial to City of Hope sites | 1 | Investing.com | ||
| 19.03. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01 | 3 | GlobeNewswire (USA) | ||
| 18.03. | Greenwich LifeSciences to present trial data at AACR meeting | 1 | Investing.com | ||
| 18.03. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Upcoming AACR Meeting | 1 | GlobeNewswire (USA) | ||
| 17.03. | Greenwich LifeSciences reports reduced cancer recurrence in trial | 14 | Investing.com | ||
| 17.03. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01 | 235 | GlobeNewswire (Europe) | STAFFORD, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial... ► Artikel lesen |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,30 | 0,00 % | Ihre wichtigsten Termine: Alle Blicke auf: Fraport, Biontech, Nagarro, Freenet & Intercontinental Exchange | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Deutschland:... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,400 | 0,00 % | Could Viking Therapeutics Be the Next Eli Lilly? | ||
| KUROS BIOSCIENCES | 23,920 | -1,16 % | EILMELDUNG bei Kuros Biosciences: Was sich hinter den Kulissen tut - Meine Analyse im Detail | ||
| ABIVAX | 105,20 | -0,66 % | Abivax S.A. - 6-K, Report of foreign issuer | ||
| CARDIFF ONCOLOGY | 1,554 | +0,58 % | Cardiff Oncology kündigt Webcast zu neuen Studiendaten für Krebsmedikament an | ||
| IOVANCE BIOTHERAPEUTICS | 3,165 | -0,47 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates | 1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous Endometrial... ► Artikel lesen | |
| ARGENX | 707,00 | +1,09 % | DEUTSCHE BANK RESEARCH stuft Argenx auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Argenx von 725 auf 750 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Emmanuel Papadakis aktualisierte in einer... ► Artikel lesen | |
| DENALI THERAPEUTICS | 16,445 | -0,96 % | Biogen, Denali discontinue Parkinson's drug after trial fails | ||
| INSMED | 93,75 | -0,57 % | Infex chases after Insmed with bronchiectasis trial win | ||
| CAPRICOR | 25,500 | +0,24 % | Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary... ► Artikel lesen | |
| REVOLUTION MEDICINES | 131,75 | -0,42 % | Revolution Medicines to host webcast on phase 3 trial results | ||
| ZEVRA THERAPEUTICS | 8,940 | 0,00 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 16,955 | -0,35 % | Syndax stellt neue Daten zu Revumenib auf ASCO-Jahrestagung vor | ||
| PALVELLA THERAPEUTICS | 99,00 | +1,02 % | Palvella Therapeutics Inc.: Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology | 100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malformations Investigator Global Assessment Bleeding scale (cVM-IGA Bleeding)... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 10,365 | -7,83 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors | SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D.,... ► Artikel lesen |
GREENWICH LIFESCIENCES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,030 (-0,11 %) liegt der Kurs bei 27,160 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GREENWICH LIFESCIENCES INC finden Sie auf Wallstreet Online.